Risk Factors in Nephrotoxicity

  • C. A. Vaamonde
Chapter
Part of the Developments in Nephrology book series (DINE, volume 11)

Abstract

The majority of drugs commonly used in clinical practice have a low incidence of renal toxicity. In assessing the frequency of nephrotoxicity, it is clear that most renal injury tends to cluster around certain patients and specific clinical situations. Because nephrotoxicity may limit the clinical usefulness of many diagnostic and therapeutic agents, recognition of factors associated with a greater risk for renal injury is important [1–3].

Keywords

Aspirin Dehydration PGE2 Naproxen Glomerulonephritis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vaamonde, CA.: Antibiotic-induced nephrotoxicity. In Nephrology, Volume 1, edited by Robinson, R.R., Proceedings IXth. International Congress of Nephrology, Los Angeles, CA, New York, Karger, S., 1984, pp 844–868.Google Scholar
  2. 2.
    Appel, G.B., Neu, H.C.: The nephrotoxicity of antimicrobial agents (three parts). N. Engl. J. Med., 296: 663, 1977.PubMedCrossRefGoogle Scholar
  3. 3.
    Smith, T.R., Smith, CR.: Risk factors for aminoglycoside nephrotoxicity. In The Aminoglycosides. Microbiology, Clinical Use, and Toxicology, edited by Whelton, A., Neu, H.C., New York, Marcel Dekker, 1982, pp 401–415.Google Scholar
  4. 4.
    Cockcroft, D., Gault, M.H.: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31, 1976.PubMedCrossRefGoogle Scholar
  5. 5.
    Ehrnebo, M., Agurell, S., Jailing, B., Boreus, L.O.: Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults. Eur. J. Clin. Pharmacol., 3: 189, 1971.PubMedCrossRefGoogle Scholar
  6. 6.
    Krasner, J., Giacoia, G.P., Yaffe, S.F.:Drug-protein binding in the newborn infant. Ann. N.Y. Scad. Sci., 226: 101, 1973.CrossRefGoogle Scholar
  7. 7.
    Rane, A., Wilson, J.T.: Clinical pharmacokinetics in infants and children. Clin. Pharmacokinetics 1: 2, 1976.CrossRefGoogle Scholar
  8. 8.
    Cafruny, E.F.: Effects of drugs and toxins on the kidney. In Pediatric Kidney Disease, edited by Edelman, Jr., CM., Boston, Little, Brown. Co., 1978, pp 935–939.Google Scholar
  9. 9.
    Shafi, T., Chou, S., Porush, J., Shapiro, W.B.: Infusion intravenous pyelography and renal function effects in patients with chronic renal insufficiency. Arch. Intern. Med., 138: 1218, 1978.PubMedCrossRefGoogle Scholar
  10. 10.
    Swartz, R.D., Rubin, J.E., Leeming, B.W., Silva, P.: Renal failure following major angiography. Am. J. Med., 65: 31, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Van Zee, B.E., Hoy, W.E., Talley, T.E., Jaenike, J.R.: Renal injury associated with intravenous pyelography in non-diabetic and diabetic patients. Ann. Intern. Med., 89: 51, 1978.Google Scholar
  12. 12.
    Heneghan, M.: Contrast-induced acute renal failure. Editorial. Am. J. Roentgenol., 131: 1113, 1978.Google Scholar
  13. 13.
    Byrd, L., Sherman, R.L.: Radiocontrast-induced acute renal failure: A clinical and pathophysiological review. Medicine 58: 270, 1979.PubMedCrossRefGoogle Scholar
  14. 14.
    Canales, CO., Smith, G.H., Robinson, J.C, Remmers, A.R., Sarles, H.E.: Acute renal failure after the administration of iopanoic acid as a cholecystographic agent. N. Engl. J. Med., 281: 89, 1969.PubMedCrossRefGoogle Scholar
  15. 15.
    Berezin, A.F.: Acute renal failure, diabetes mellitus, and scanning. Ann. Intern. Med., 86: 829, 1977.PubMedGoogle Scholar
  16. 16.
    Hanaway, J., Black, J.: Renal failure following contrast injection for computerized tomography. J.A.M.A., 238: 2056, 1977.PubMedCrossRefGoogle Scholar
  17. 17.
    Takazahura, E., Sawabu, N., Handa, A., Takada, A., Shinoda, A,, Takeuchi, J.: Intrarenal vascular changes with age and disease. Kidney Int., 2: 224, 1972.CrossRefGoogle Scholar
  18. 18.
    Hollenberg, N.K., Adams, D.F., Solomon, H.S., Rashid, A., Abrams, H.L., Merrill, J.P.: Senescence and the renal vasculature in normal man. Circ. Res., 34: 309, 1974.PubMedGoogle Scholar
  19. 19.
    Ansari, Z., Baldwin, D.S.: Acute renal failure due to radiocontrast agents. Nephron 17: 28, 1976.PubMedCrossRefGoogle Scholar
  20. 20.
    D’Elia, J.A., Gleason, R.E., Alday, M., Malarick, C., Godley, K., Warram, J., Kaldany, A., Weinrauch, L.A.: Nephrotoxicity from angiographic contrast material. A prospective study. Am. J. Med., 72: 719, 1982.PubMedCrossRefGoogle Scholar
  21. 21.
    Teruel, J.L., Mareen, R., Onaindia, J.M., Serrano, A., Quereda, C, Ortuno, J.: Renal impairment caused by intravenous urography. A prospective study. Arch. Intern. Med., 141: 1271, 1981.PubMedCrossRefGoogle Scholar
  22. 22.
    Coggins, C.H., Fang, L.S-T: Acute renal failure associated with antibiotics, anesthetic agents, and radiographic contrast agents. In. Acute Renal Failure, edited by Brenner, B.M., and Lazarus, J.M., Philadelphia, W.B. Saunders Co., 1983, pp 283–320.Google Scholar
  23. 23.
    Harkonen, S., Kjellstrand, K.M.: Exacerbation of diabetic renal failure following intravenous pyelography. Am.J.Med., 63: 939, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Dudzinski, P.J., Pétrone, A.F., Peroff, M., Callaghan, E.E.: Acute renal failure following high-dose excretory urography in dehydrated patients. J. Urol., 106: 619, 1971.PubMedGoogle Scholar
  25. 25.
    Kamdar, A., Weidmann, P., Makoff, D.L., Massry, S.G.: Acute renal failure following intravenous use of radiographic contrast dyes in patients with diabetes mellitus. Diabetes 26: 643, 1977.PubMedCrossRefGoogle Scholar
  26. 26.
    Veseley, D.L., Mintz, D.H.: Acute renal failure in insulindependent diabetics. Episodes secondary to intravenous pyelography. Arch. Intern. Med., 138: 1858, 1978.CrossRefGoogle Scholar
  27. 27.
    Pillay, V.K., Robbins, P.C., Schwartz, F.D., Kark, R.M.: Acute renal failure following intravenous urography in patients with long-standing diabetes mellitus and azotemia. Radiology 95: 633, 1970.PubMedGoogle Scholar
  28. 28.
    Barshay, M.E., Kay, J.H., Goldman, R., Coburn, J.W.: Acute renal failure in diabetic patients after infusion pyelography. Clin. Nephrol., 1: 35, 1973.PubMedGoogle Scholar
  29. 29.
    Diaz-Buxo, J.A., Wagoner, R.D., Hattery, R.R., Palumbo, P.J.: Acute renal failure after excretory urography. Ann. Intern. Med., 83: 155, 1975.PubMedGoogle Scholar
  30. 30.
    Shieh, S.D., Hirsch, S.R., Boshell, B.R., Pino, J.A., Alexander, L.J., Witten, D.M., Friedman, E.A.: Low risk of contrast media-induced acute renal failure in nonazotemic type 2 diabetes melliuts. Kidney Int., 21: 739, 1982.PubMedCrossRefGoogle Scholar
  31. 31.
    Mason, R.A., Arbeit, L.A., Giron, F.: Renal dysfunction after arteriography. J.A.M.A., 253: 1001, 1985.PubMedCrossRefGoogle Scholar
  32. 32.
    Teixeira, R.B., Kelley, J., Vaamonde, C.A.: Absence of sensitivity to the renal toxic effects of radiographic contrast material in the diabetic rat. Clin. Res., 30: 464A, 1982.Google Scholar
  33. 33.
    Reed, J.R., Williams, R.H., Luke, R.G.: The renal hemodynamic response to diatrizoate in normal and diabetic rats. Invest. Radiol., 18: 536, 1983.PubMedCrossRefGoogle Scholar
  34. 34.
    DeFronzo, R.A., Humphrey, R.L., Wright, J.R., Cooke, C.R.: Acute renal failure in multiple myeloma. Medicine 54: 209, 1975.PubMedCrossRefGoogle Scholar
  35. 35.
    Cochran, S.T., Waisman, J., Pagani, J.J., Cahill, P.: Nephrotoxicity of epinephrine-assisted venography. Invest. Radiol., 17: 583, 1982.PubMedCrossRefGoogle Scholar
  36. 36.
    Fang, L.S., Sirota, R.A., Ebert, T.H., Lichtenstein, N.S.: Low fractional excretion of sodium with contrast mediainduced acute renal failure. Arch. Intern. Med., 140: 531, 1980PubMedCrossRefGoogle Scholar
  37. 37.
    Avner, E.D., Ellis, D., Jaffe, R., Bowen, A’D.: Neonatal radiocontrast nephropathy simulating infantile polycystic kidney disease. J. Pediatrics 100: 85, 1982.CrossRefGoogle Scholar
  38. 38.
    Berdon, W.E., Schwartz, R.H., Becker, J., Baker, D.H.: Tamm-Horsfall proteinuria. Radiology 92: 714, 1969.PubMedGoogle Scholar
  39. 39.
    Hayman, L.A., Evans, R.A., Fahr, L.M., Hinck, V.C.: Renal consequences of rapid high dose contrast CT: Am. J. Roent., 134: 553, 1980.Google Scholar
  40. 40.
    Eisenberg, R.L., Bank, W.O., Hedgcock, M.W.: Renal failure after angiography. Am. J. Med., 68: 43, 1980.PubMedCrossRefGoogle Scholar
  41. 41.
    Rahimi, A., Edmondson, R.P.S., Jones, N.F.: Effect of radiocontrast media on kidneys of patients with renal disease. Br. J. Med., 282: 1194, 1981.CrossRefGoogle Scholar
  42. 42.
    Nicot, G.S., Merle. L.J., Charmes, J.P., Valette, J.P., Nouaille, Y.D., Lachatre, G.F., Leroux-Robert, C: Transient glomerular proteinuria, enzymuria, and nephrotoxic reaction induced by radiocontrast media. J.A. M.A., 252: 2432, 1984.PubMedCrossRefGoogle Scholar
  43. 43.
    Snyder, H.S., Killen, D.A., Foster, J.H.: The influence of mannitol in toxic reactions to contrast angiography. Surgery 64: 640, 1968.PubMedGoogle Scholar
  44. 44.
    Old, CS., Lehrner, L.M.: Prevention of radiocontrastinduced acute renal failure with mannitol. Lancet 1: 885, 1980.PubMedCrossRefGoogle Scholar
  45. 45.
    Anto, H.R., Chou, S-Y, Porush, J.G., Shapiro, W.B.: Mannitol prevention of acute renal failure associated with infusion intravenous pyelography. Clin. Res., 27: 407A, 1979.Google Scholar
  46. 46.
    Lane, A.Z., Wright, G.E., Blair, D.C.: Ototoxicity and nephrotoxicity of amikacin. Am. J. Med., 62: 911, 1977.PubMedCrossRefGoogle Scholar
  47. 47.
    The EORTC International Antimicrobial Therapy Project Group: Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J. Infect. Dis., 137: 14, 1978.CrossRefGoogle Scholar
  48. 48.
    Lau, W*K., Young, L.S., Black, R.E., Winston, D.J., Linne, S.R., Weinstein, R.J., Hewitt, W.L.: Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/ carbenicillin in leukopenic patients. Am. J. Med., 62: 959, 1977.CrossRefGoogle Scholar
  49. 49.
    Moore, R.D., Smith, CR., Lipsky, J.J., Mellits, E.D., Lietman, P.S.: Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann. Intern. Med., 100: 352, 1984.PubMedGoogle Scholar
  50. 50.
    Zakauddin, S., Adelman, R.: Urinary enzyme activity in neonates receiving gentamicin therapy. Clin. Res., 26: 142A, 1978.Google Scholar
  51. 51.
    Cowan, R.H., Jukkola, A.F., Arant, B.S., Jr.: Pathophysiological evidence of gentamicin (G) nephrotoxicity in the neonatal puppy. Kidney Int., 14: 628, 1978.Google Scholar
  52. 52.
    Marre, R., Tarara, N., Louton, T., Sack, K.: Age-dependent nephrotoxicity and the pharmacokinetics of gentamicin in rats. Eur. J. Pediatr., 133: 25, 1980.PubMedCrossRefGoogle Scholar
  53. 53.
    Karniski, L., Chonko, A., Stewart, R., Cuppage, F., Hodges, C: The effects of gentamicin (G) on renal function in the sexually mature vs. sexually immature rabbits. Kidney Int., 14: 726, 1978.Google Scholar
  54. 54.
    Smith, CR., Maxwell, R.R., Edwards, C.G., Rogers, J.F., Lietman, P.S.: Nephrotoxicity induced by gentamicin and amikacin. Johns Hopkins Med. J., 142: 85, 1978.PubMedGoogle Scholar
  55. 55.
    Reyman, M.T., Bradac, J.A., Cobbs, CG., Dismukes, W.E.: Correlation of aminoglycoside dosage with serum concentration during therapy of serious gram-negative bacillary disease. Antimicrob. Agents Chemother., 16: 353, 1979.Google Scholar
  56. 56.
    Bennett, W.M., Hartnett, M.N., Gilbert, D.N., Houghton, D., Porter, CA.: Effect of sodium intake on gentamicin nephrotoxicity in the rat. Proc. Soc. Exp. Biol. Med., 151: 736, 1976.PubMedGoogle Scholar
  57. 57.
    Lecompte, J., Dumont, L., Hill, J., Souichi, P.D., Lelorier, J.: Effect of water deprivation and rehydration on gentamicin disposition in the rat. J. Pharmacol. Exp. Ther., 218: 231, 1981.PubMedGoogle Scholar
  58. 58.
    Adelman, R.D.: Sodium depletion and diuretics in relation to aminoglycoside nephrotoxicity, In Nephrotoxicity, Ototoxicity of Drugs, edited by Fillastre, J.P., Rouen, Editions Inserm, 1982, pp 213–224.Google Scholar
  59. 59.
    Finn, W.F., Fernandez-Repollet, E.: Contribution of intravascular volume contraction to gentamicin nephrotoxicity. Kidney. Int., 21: 217, 1982.Google Scholar
  60. 60.
    Kahn, T.: Effect of furosemide on gentamicin and netilmicin nephrotoxicity. Kidney. Int., 12: 527, 1977.Google Scholar
  61. 61.
    DeRougemont, D,, Oeschger, A., Konrad, L., Theil, G., Torhorst, J., Wenk, M., Wunderlich, P., Brunner, F.P.: Gentamicin-induced acute renal failure in the rat: Effect of dehydration, DOCA-saline and furosemide. Nephron 29: 176, 1981.CrossRefGoogle Scholar
  62. 62.
    Chiu, P.J.S., Miller, G.H., Long, J.F., Waitz, J.A.: Renal uptake and nephrotoxicity of gentamicin during urinary alkalinization in rats. Clin. Exp. Pharmacol. Physiol., 6: 317, 1979.PubMedCrossRefGoogle Scholar
  63. 63.
    Elliott, W.C., Parker, R.A., Houghton, D.C., Gilbert, D.N., Porter, G.A., Defehr, J., Bennett, W.M.: Effect of sodium bicarbonate and ammonium chloride ingestion in experimental gentamicin nephrotoxicity in rats. Res. Comm. Chem. Pathol. Pharmacol., 28: 483, 1980.Google Scholar
  64. 64.
    Brinker, K.R., Bulger, R.E., Dobyan, D.C., Stacey, T.R., Southern, P.M., Henrich, W.L., Cronin, R.E.: Effect of potassium depletion on gentamicin nephrotoxicity. J. Lab. Clin. Med., 98: 292, 1981.PubMedGoogle Scholar
  65. 65.
    Yarger, W.E.: Effect of potassium depletion on gentamicininduced acute renal failure. Clin. Res., 26: 806A, 1978.Google Scholar
  66. 66.
    Rankin, L.I., Krous, H., Fryer, A.W., Whang, R.: Enhancement of gentamicin nephrotoxicity by magnesium depletion in the rat. Min. Electr. Metab., 10: 199, 1984.Google Scholar
  67. 67.
    Cabrera, J., Arroyo, V., Ballesta, A.M.: Aminoglycoside nephrotoxicity in cirrhosis: value of urinary beta 2 microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 82: 97, 1982.PubMedGoogle Scholar
  68. 68.
    Humes, H.D., Weinberg, J.M., Knauss, T.C.: Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am. J. Kidney. Dis., 2: 5, 1982.PubMedGoogle Scholar
  69. 69.
    Kaloyanides, G,J., Pastoriza-Munoz, E.: Aminoglycoside nephrotoxicity. Kidney. Int., 18: 571, 1980.CrossRefGoogle Scholar
  70. 70.
    Soberon, L., Bowman, R.L., Pastoriza-Munoz, E., Kaloyanides, G.J.: Comparative nephrotoxicities of gentaraicin, netilmicin and tobramycin in the rat. J. Pharmacol. Exp. Ther., 210: 334, 1979.PubMedGoogle Scholar
  71. 71.
    Senekjian, H.O., Knight, T.F., Weinman, E.J.: Micropuncture study of the handling of gentamicin by the rat kidney. Kidney. Int., 19: 416, 1981.PubMedCrossRefGoogle Scholar
  72. 72.
    Sheth, A.U., Senekjian, H.O., Babino, H., Knight, T.F., Weinman, E.J.: Renal handling of gentamicin by the Munich-Wistar rat. Am. J. Physiol., 10: F645, 1981.Google Scholar
  73. 73.
    Pastoriza-Munoz, E., Timmerman, D., Kaloyanides, G.J.: Renal transport of netilmicin in the rat. J. Pharmacol. Exp.Ther., 228: 65, 1984.PubMedGoogle Scholar
  74. 74.
    Smith, C.R., Lietman, P.S.: Comparative clinical trials of aminoglycosides, In The Aminoglycosides. Microbiology, Clinical Use, and Toxicology, edited by Whelton, A., Neu, H.C., New York, Marcel Dekker, 1982, pp 497–509.Google Scholar
  75. 75.
    Walker, B.D., Gentry, L.O.: A randomized, comparative study of tobramycin and gentamicin in treatment of acute urinary infections. J. Infect. Dis., 134 (Suppl): S146, 1976.PubMedCrossRefGoogle Scholar
  76. 76.
    Schentag, J.J., Plaut, M.E., Cerra, F.b., Wels, P.B., Walczak, P., Buckley, R.J.: Aminoglycoside nephrotoxicity in critically ill surgical patients. J. Surg. Res., 26: 270, 1979.CrossRefGoogle Scholar
  77. 77.
    Smith, C.R., Lipsky, J.J., Laskin, O.L., Hellman, D.B., Mellits, E.D., Longstreth, J., Lietman, P.S.: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N. Engl. J. Med., 302: 1106, 1980.PubMedCrossRefGoogle Scholar
  78. 78.
    Lerner, S.A., Seligsohn, R., Matz, G.J.: Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. Am. J. Med., 62: 959, 1977.CrossRefGoogle Scholar
  79. 79.
    Lerner, A.M., Cone, L.A., Jansen, W., Reyes, M.P., Blair, D.C., Wright, G.E., Lorber, R.R.: Randomized, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1: 1123, 1983.PubMedCrossRefGoogle Scholar
  80. 80.
    Houghton, D.C., Plamp, CE., DeFehr, J.M., Bennett, W.M., Porter, G.A., Gilbert, D.: Gentamicin and tobramycin nephrotoxicity. Am. J. Pathol., 93: 137, 1978.PubMedGoogle Scholar
  81. 81.
    Luft, F.C., Bloch, R., Sloan, R.S., Yum, M.N., Maxwell, D.R.: Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J. Infect. Dis., 138: 541, 1978.PubMedCrossRefGoogle Scholar
  82. 82.
    Gilbert, D.N., Plamp, CE., Starr, P., Bennett, W.M., Houghton, D.C., Porter, G.A.: Comparative nephrotoxicity of gentamicin and tobramycin in rats. Antimicrob. Agents Chemother., 13: 34, 1978.PubMedGoogle Scholar
  83. 83.
    Ormsby, A.M., Parker, R.A., Plamp, C.E., Stevens, P., Houghton, D.C., Gilbert, D.N., Bennett, W.M.: Comparison of the nephrotoxic potential of gentamicin tobramycin and netilmicin in the rat. Curr. Therap. Res., 25: 335, 1979.Google Scholar
  84. 84.
    Houghton, D.C., Plamp, CE., Gilbert, D.N., Kolhepp, S., Bennett, W.M., Porter, CA., DeFehr, J., Webb, R.: Amikacin nephrotoxicity in the rat. J. Environ. Pathol. Toxicol., 4: 227, 1980.Google Scholar
  85. 85.
    Luft, F.C., Yum, M.N., Kleit, S.A.: Comparative nephrotoxicity of netilmicin and gentamicin in rats. Antimicrob. Agents Chemother., 10: 845, 1976.PubMedGoogle Scholar
  86. 86.
    Luft, F.C., Rankin, L.I., Sloan, R.S., Fineberg, N.S., Yun, M.N., Wong, L.: Comparative low-dose nephrotoxicity of dibekacin, gentamicin and tobramycin. J. Antimicrob. Chemother., 9: 297, 1982.PubMedCrossRefGoogle Scholar
  87. 87.
    Dalhgren, J.C, Anderson, E.T., Hewitt, W.L.: Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob. Agents Chemother., 8:58, 1975,Google Scholar
  88. 88.
    Frame, P.T., Phair, J.P., Watanakunakorn, C, Bannister, T.W.P.: Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J. Infect. Dis., 135: 952, 1977.PubMedCrossRefGoogle Scholar
  89. 89.
    Bennett, W.M., Plamp, CE., Gilbert, D.N., Parker, R.A., Porter, CA.: The influence of dosage regimen on experimental gentamicin nephrotoxicity:dissociation of peak serum levels from renal failure. J. Infect. Dis., 140: 576, 1979.PubMedCrossRefGoogle Scholar
  90. 90.
    Powell, S.H., Thompson, W.L., Luthe, M.A., Stern, R.C, Grossniklaus, D.A., Bloxham, D.D., Groden, D.L., Jacobs, M.R., DiScenna, A.O., Cash, H.A., Klinger, J.D.: Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies with gentamicin, netilmicin, and tobramycin. J. Inf. Dis., 147: 918, 1983.CrossRefGoogle Scholar
  91. 91.
    Schentag, J.J., Cumbo, T.J., Jusko, W.J., Plaut, M.E.: gentamicin tissue accumulation and nephrotoxic reactions. J.A.M.A., 240: 2067, 1978.PubMedCrossRefGoogle Scholar
  92. 92.
    Mazze, R.I., Coussins, M: Combined nephrotoxicity of gentamicin and methoxyflurane anesthesia in man. Br. J. Anaesth., 45: 394, 1973.PubMedCrossRefGoogle Scholar
  93. 93.
    Gonzalez-Vitale, J.C., Hayes, D.M., Cvitkovic, E., Sternberg, S.S.: Acute renal failure after Cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies. Cancer. Treat. Rep., 62: 693, 1978.PubMedGoogle Scholar
  94. 94.
    Churchill, D.N., Seeley, J: Nephrotoxicity associated with combined gentamicin-araphotericin B therapy. Nephron 19: 176, 1977.PubMedCrossRefGoogle Scholar
  95. 95.
    Butkus, D.E., DeTorrente, A, Terman, D.S.: Renal failure following gentamicin in combination with clindamycin. Nephron 17: 307, 1976.PubMedCrossRefGoogle Scholar
  96. 96.
    Wade, J.C, Smith, CR., Petty, B.G., Lipsky, J.J., Conrad, G., Ellner, J., Lietman, P.S.: Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet 2: 604, 1978.PubMedCrossRefGoogle Scholar
  97. 97.
    Lawson, D.H., Macadam, R.F., Singh, H., Garras, H., Hartz, S., Turnbull, D., Linton, A.L.: Effect of furosemide on antibiotic-induced renal damage in rats. J. Infect. Dis., 126: 593, 1972.PubMedCrossRefGoogle Scholar
  98. 98.
    Whiting, P.H., Barber, H.E., Petersen, J.: The effect of furosemide and piretamide on the renal clearance of gentamicin in man. Br. J. Clin. Pharmac, 12: 795, 1981.Google Scholar
  99. 99.
    Higa, E.M.S., Schor, N., Boim, M.A., Ajzen, H., Ramos, O.L.: Prostaglandin inhibition in gentamicin and tobramycin nephrotoxicity. Clin. Res., 30: 450A, 1982.Google Scholar
  100. 100.
    Giamarellou, H., Metzikoff, C, Parachristophorou, A.S., Dontas, A.S., Daikos, G.K.: Prospective comparative evaluation of gentamicin or gentamicin-plus cephalothin in the production of nephrotoxicity in man. J. Antimicrob. Chemother., 5: 581, 1979.PubMedCrossRefGoogle Scholar
  101. 101.
    Harrison, W.O., Silverblatt, F.J., Turck, M.: Gentamicin nephrotoxicity: failure of three cephalosporins to potentiate injury in rats. Antimicrob. Agents Chemother., 8: 209, 1975.PubMedGoogle Scholar
  102. 102.
    Bloch, R., Luft, F.C., Rankin, L.I., Sloan, R.S., Yum, M.N., Maxwell, D.R.: Protection from gentamicin nephrotoxicity by cephalothin and carbenicillin. Antimicrob. Agents Chemother., 15: 46, 1979.PubMedGoogle Scholar
  103. 103.
    Barza, M., Pinn, V., Tanguay, P., Murray, T.: Nephrotoxicity of newer cephalosporins and aminoglycosides alone and in combination in a rat model. J. Antimicrob. Chemother., 4 (Suppl A): 59, 1978.PubMedGoogle Scholar
  104. 104.
    Hows, J.M., Palmer, S., Want, S., Dearden, C, Gordon-Smith, E.C.: Serum levels of cyclosporin A and nephrotoxicity in bone marrow transplant patients. Lancet 2: 145, 1981.PubMedCrossRefGoogle Scholar
  105. 105.
    Whiting, P.H., Simpson, J.G.: The enhancement of cyclosporin A-induced nephrotoxicity of gentamicin. Biochem. Pharmacol., 32: 2025, 1983.PubMedCrossRefGoogle Scholar
  106. 106.
    Bennett, W.M., Parker, R.A., Elliott, W.C., Gilbert, D.N., Houghton, D.C.: Sex-related differences in the susceptibility of rats to gentaraicin nephrotoxicity. J. Infect. Dis., 145: 370, 1982.PubMedCrossRefGoogle Scholar
  107. 107.
    Kourilsky, O., Solez, K., Morel-Maroger, L., Whelton, A., Duhoux, P., Sraer, J.D.: The pathology of acute renal failure due to interstitial nephritis in man with comments on the role of interstitial inflammation and sex in gentamicin nephrotoxicity. Medicine (Baltimore) 61: 258, 1982.CrossRefGoogle Scholar
  108. 108.
    Vaamonde, C.A., Gouvea, W., Owens, B., Alpert, H.C.: Sex does not influence the protection against gentamicin nephrotoxicity in the diabetic rat. Kidney. Int., 25: 238, 1984.Google Scholar
  109. 109.
    Hsu, C.H., Kurtz, T.W., Easterling, R.E., Weiler, J.M.: Potentiation of gentamicin nephrotoxicity by metabolic acidosis. Proc. Soc. Exp. Biol. Med., 146: 894, 1974.PubMedGoogle Scholar
  110. 110.
    Solez, K., Silvia, C.B., Craig, T., Stout, R., Whelton, A.: Adverse effect of amino acid mixtures in experimental aminoglycoside toxicity. Clin. Res., 28: 462A, 1980.Google Scholar
  111. 111.
    Hardaker, W.T., Jr., Stone, R.A., McCoy, R.: Platinum nephrotoxicity. Cancer 34: 1030, 1974.PubMedCrossRefGoogle Scholar
  112. 112.
    Gonzalez-Vitale, J.C., Hayes, D.M., Cvitkovic, E., Sternberg, S.S.: The renal pathology in clinical trials of Cis-platinum (II) diamminedichloride. Cancer 39: 1362, 1977.CrossRefGoogle Scholar
  113. 113.
    Gonzalez-Vitale, J.C., Hayes, D.M., Cvitkovic, E., Sternberg, S.S.: Acute renal failure after Cis-Dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies. Cancer Treat. Rep., 62:693, 1978,PubMedGoogle Scholar
  114. 114.
    Blachley, J.D., Hill, J.B.: Renal and electrolyte disturbances associated with cisplatin. Ann. Intern. Med., 95: 628, 1981.PubMedGoogle Scholar
  115. 115.
    Editorial: Cisplatin. Lancet 1: 374, 1982.Google Scholar
  116. 116.
    Rossof, A.H., Slayton, R.E., Perlia, C.P.: Preliminary clinical experience with cis-diamminedichloro-platinum (II) (NSC 119875, CACP). cancer 30: 1451, 1972.PubMedCrossRefGoogle Scholar
  117. 117.
    Dentino, M., Luft, F.C., Yum, M.N., Williams, S.D., Einhorn, L.H.: Long terra effect of Cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41: 1274, 1978.PubMedCrossRefGoogle Scholar
  118. 118.
    Hrushesky, W.J.M., Shimp, W., Kennedy, B.J.: Lack of agedependent cisplatin nephrotoxicity. Am. J. Med., 76: 579, 1984.PubMedCrossRefGoogle Scholar
  119. 119.
    Pickering, D.G., Phillips, R.H., Ashford, R.F.: Cisplatin in obstructive uropathy. Lancet 2: 588, 1980.PubMedCrossRefGoogle Scholar
  120. 120.
    Hayes, D.M., Cvitkovic, E., Goldberg, R.B., Sheiner, E., Helson, L., Krahoff, I.H.: High dose cis-platinum diammine dichloride: Amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372, 1977.PubMedCrossRefGoogle Scholar
  121. 121.
    Jacobs, C, Bertino, J.R., Goffinet, D.R.: 24-hour infusion of cis-platinum in head and neck cancers. Cancer 42: 2135, 1978.PubMedCrossRefGoogle Scholar
  122. 122.
    Stark, J.J., Howell, S.B.: Nephrotoxicity of cisplatinum (II) dichlorodiammine. Clin. Pharmacol. Therap., 23: 461, 1978.Google Scholar
  123. 123.
    Vogl, S.E., Zavarinos, T. Kaplan, B.H.: Toxicity of Cisdiamminechloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration. Cancer 45: 11, 1980.PubMedCrossRefGoogle Scholar
  124. 124.
    Garnick, M.B., Mayer, R.J., Abelson, H.T.: Acute renal failure associated with cancer treatment. In Acute Renal Failure, edited by Brenner, B.M., and Lazarus, J.M., Boston, Little, Brown, and Co., 1983, pp 527–554.Google Scholar
  125. 125.
    Earhart, R.H., Martin, P.A., Tutsch, K.D., Erturk, E., Wheeler, R.H., Bull, F.E.: Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. Cancer Res., 43: 1187, 1983.PubMedGoogle Scholar
  126. 126.
    Ozols, R.F., Corden, B.J., Jacob, J., Wesley, M.N., Ostchega, Y., Young, R.C.: High-dose cisplatin in hypertonic saline. Ann. Intern. Med., 100: 19, 1984.PubMedGoogle Scholar
  127. 127.
    Kawamura, J., Soeda, A., Yoshida, O.: Nephrotoxicity of cisdiamminedichloroplatinum (II) (cis-platinum) and the additive effect of antibiotics: morphological and functional observations in rats. Toxicol. Appl. Pharmacol., 58: 475, 1981.PubMedCrossRefGoogle Scholar
  128. 128.
    Ross, D.A., Gale, G.R.: Reduction of the renal toxicity of cis-dichlorodiammineplatinum (II) by probenecid. Cancer Treat. Rep., 63: 781, 1979.PubMedGoogle Scholar
  129. 129.
    Daley-Yates, P.T., McBrien, D.C.H.: Enhancement of cisplatin nephrotoxicity by probenecid. Cancer Treat. Rep., 68: 445, 1984.PubMedGoogle Scholar
  130. 130.
    Van Barneveld, P.W.C., Sleiffer, D.T., Van der Mark, T.W., Mulder, N.H., Donker, A.J.M., Meijer, S., Schraffordt-Koops, H., Sluiter, H.J., Peset, R.: Influence of platinum-induced renal toxicity on bleomycin-induced pulmonary toxicity in patients with disseminated testicular carcinoma. Oncology 41: 4, 1984.PubMedCrossRefGoogle Scholar
  131. 131.
    Heinrich, W.L.: Nephrotoxicity of nonsteroidal antiinflammatory agents. Am. J. Kidney. Dis., 2: 478, 1983.Google Scholar
  132. 132.
    Calin, A.: In common clinical usage nonsteroidal antiinflammatory drugs infrequently produce adverse effects on the kidney. Am. J. Kidney Dis., 2: 485, 1983.PubMedGoogle Scholar
  133. 133.
    Levenson, D.J., Simmons, C.E., Jr., Brenner, B.M.: Arachidonic acid metabolism, prostaglandins and the kidney. Am. J. Med., 72: 354, 1982.PubMedCrossRefGoogle Scholar
  134. 134.
    Garella, S., Matarese, R.A.: Renal effects of prostaglandins and clinical adverse effects of nonsteroidal antiinflammatory agents. Medicine 63: 165, 1984.PubMedCrossRefGoogle Scholar
  135. 135.
    Walshe, J.J., Venuto, R.C.: Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann. Intern. Med., 91: 47, 1979.PubMedGoogle Scholar
  136. 136.
    Kimberly, R.P., Gill, J.R., Bowden, R.E.: Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erithematosus. Ann. Intern. Med., 89: 336, 1978.PubMedGoogle Scholar
  137. 137.
    Berg, K.F.: Acute effects of acetylsalicylic acid in patients with chronic renal failure. Europ. J. Clin. Pharmacol., 11: 111, 1977.CrossRefGoogle Scholar
  138. 138.
    Gary, N.E., Dodelson, R., Eisinger, R.P.: Indomethacininduced acute renal failure. Am. J. Med., 69: 135, 1980.PubMedCrossRefGoogle Scholar
  139. 139.
    Brezin, J.H., Katz, S.M., Schwartz, A.B., Chinitz, F.L.: Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. New. Engl. J. Med., 301: 1271, 1979.PubMedCrossRefGoogle Scholar
  140. 140.
    Katz, S.M., Capaldo, R., Everts, E.A., DiGregorio, J.G.: Tolmetin. Association with reversible renal failure and acute interstitial nephritis. J.A.M.A., 246: 243, 1981.PubMedCrossRefGoogle Scholar
  141. 141.
    Bender, W.L., Whelton, A., Beschorner, W.E., Darwish, M.O., Hall-Craggs, M., Solez, K.: Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal antiinflammatory drugs. Immunologic characterization of the inflammatory infiltrate. Am. J. Med., 76: 1006, 1984.PubMedCrossRefGoogle Scholar
  142. 142.
    Boyer, T.D., Zia, P., Reynolds, T.B.: Effect of indomethacin and prostaglandin Al on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77: 215, 1979.PubMedGoogle Scholar
  143. 143.
    Tan, S.Y., Shapiro, R., Franco, R.: Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism, Ann. Intern. Med., 90: 783, 1979.PubMedGoogle Scholar
  144. 144.
    Kimberly, R.P., Plotz, P.H.: Aspirin induced depression of renal function. New Engl. J. Med., 296: 418, 1977.Google Scholar
  145. 145.
    Stoff, J.S., Clive, D.M.: Role of prostaglandins in acute renal failure. In Acute renal Failure, edited by Brenner, B.M., Lazarus, G.M., Boston, Little, Brown, R. Co., 1983, pp 157–174.Google Scholar
  146. 146.
    Kleinknecht, C, Broyer, M., Gubler, M.C., Palcoux, J.B.: Irreversible renal failure after indomethacin in steroidresistant nephrosis. New Engl. J. Med., 302: 691, 1980.Google Scholar
  147. 147.
    Favre, L., Glasson, P., Vallotton, M.B.: Reversible acute renal failure from combined triamterene and indomethacin. A study in healthy subjects. Ann. Intern. Med., 96: 317, 1982.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1986

Authors and Affiliations

  • C. A. Vaamonde

There are no affiliations available

Personalised recommendations